Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo. [electronic resource]
Producer: 20201030Description: 13696 p. digitalISSN:- 2045-2322
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Cell Cycle -- drug effects
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Cyclin-Dependent Kinase 4 -- metabolism
- Cyclin-Dependent Kinase 6 -- metabolism
- Heterocyclic Compounds, 2-Ring -- pharmacology
- Humans
- Mitogen-Activated Protein Kinase 7 -- metabolism
- Piperazines -- pharmacology
- Protein Kinase Inhibitors -- pharmacology
- Pyridines -- pharmacology
- Thiazoles -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.